勘误表：目前针对阿尔茨海默病的肽疫苗和免疫疗法方法

IF 1.5 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Peptide Science Pub Date : 2023-04-19 DOI:10.1002/pep2.24309

{"title":"勘误表：目前针对阿尔茨海默病的肽疫苗和免疫疗法方法","authors":"","doi":"10.1002/pep2.24309","DOIUrl":null,"url":null,"abstract":"In the published article cited above, there was an error at the start of paragraph five, section two, β-Amyloid peptide vaccines where ACI-24 is introduced: the company behind ACI-24 was mis-attributed. The first sentence of the paragraph originally read: ACI-24 (AC Immune, Roche and Genentech) is designed to avoid eliciting a Th-1 response to Aβ. The sentence should read: ACI-24 (AC Immune) is designed to avoid eliciting a Th-1 response to Aβ. There was also an error at the start of paragraph six, section two, β-Amyloid peptide vaccines where ABvac40 is introduced: the company behind ABvac40 was mis-attributed. The first sentence of the paragraph originally read: ABvac40 (Axon Neuroscience SE) is designed to target the C-terminus of Aβ1–40. The sentence should read: ABvac40 (Araclon Biotech) is designed to target the C-terminus of Aβ1–40. The authors apologise for any inconvenience this may have caused. DOI: 10.1002/pep2.24309","PeriodicalId":19825,"journal":{"name":"Peptide Science","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2023-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Erratum: Current peptide vaccine and immunotherapy approaches against Alzheimer's disease\",\"authors\":\"\",\"doi\":\"10.1002/pep2.24309\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the published article cited above, there was an error at the start of paragraph five, section two, β-Amyloid peptide vaccines where ACI-24 is introduced: the company behind ACI-24 was mis-attributed. The first sentence of the paragraph originally read: ACI-24 (AC Immune, Roche and Genentech) is designed to avoid eliciting a Th-1 response to Aβ. The sentence should read: ACI-24 (AC Immune) is designed to avoid eliciting a Th-1 response to Aβ. There was also an error at the start of paragraph six, section two, β-Amyloid peptide vaccines where ABvac40 is introduced: the company behind ABvac40 was mis-attributed. The first sentence of the paragraph originally read: ABvac40 (Axon Neuroscience SE) is designed to target the C-terminus of Aβ1–40. The sentence should read: ABvac40 (Araclon Biotech) is designed to target the C-terminus of Aβ1–40. The authors apologise for any inconvenience this may have caused. DOI: 10.1002/pep2.24309\",\"PeriodicalId\":19825,\"journal\":{\"name\":\"Peptide Science\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Peptide Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pep2.24309\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peptide Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pep2.24309","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在上述发表的文章中，在第五段第二节β-淀粉样肽疫苗的开头出现了一个错误，其中引入了ACI-24：ACI-24背后的公司被错误地归因。该段的第一句话最初是：ACI-24（AC Immune、Roche和Genentech）旨在避免引发对aβ的Th-1反应。句子应为：ACI-24（AC免疫）旨在避免引发对aβ的Th-1反应。在引入ABvac40的第六段第二节β-淀粉样肽疫苗的开头也有一个错误：ABvac40背后的公司被错误归因。该段的第一句话最初是：ABvac40（Axon Neuroscience SE）旨在靶向Aβ1-40的C末端。句子应为：ABvac40（阿克隆生物技术公司）旨在靶向Aβ1-40的C末端。对于由此造成的不便，作者深表歉意。DOI:10.1002/ep2.24309

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Erratum: Current peptide vaccine and immunotherapy approaches against Alzheimer's disease

In the published article cited above, there was an error at the start of paragraph five, section two, β-Amyloid peptide vaccines where ACI-24 is introduced: the company behind ACI-24 was mis-attributed. The first sentence of the paragraph originally read: ACI-24 (AC Immune, Roche and Genentech) is designed to avoid eliciting a Th-1 response to Aβ. The sentence should read: ACI-24 (AC Immune) is designed to avoid eliciting a Th-1 response to Aβ. There was also an error at the start of paragraph six, section two, β-Amyloid peptide vaccines where ABvac40 is introduced: the company behind ABvac40 was mis-attributed. The first sentence of the paragraph originally read: ABvac40 (Axon Neuroscience SE) is designed to target the C-terminus of Aβ1–40. The sentence should read: ABvac40 (Araclon Biotech) is designed to target the C-terminus of Aβ1–40. The authors apologise for any inconvenience this may have caused. DOI: 10.1002/pep2.24309

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Peptide Science Biochemistry, Genetics and Molecular Biology-Biophysics

CiteScore

5.20

自引率

4.20%

发文量

期刊介绍： The aim of Peptide Science is to publish significant original research papers and up-to-date reviews covering the entire field of peptide research. Peptide Science provides a forum for papers exploring all aspects of peptide synthesis, materials, structure and bioactivity, including the use of peptides in exploring protein functions and protein-protein interactions. By incorporating both experimental and theoretical studies across the whole spectrum of peptide science, the journal serves the interdisciplinary biochemical, biomaterials, biophysical and biomedical research communities. Peptide Science is the official journal of the American Peptide Society.